T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial

• Published in: PloS one Vol. 7; no. 12; p. e50478
• Main Authors: Karussis, Dimitrios, Shor, Hagai, Yachnin, Julia, Lanxner, Naama, Amiel, Merav, Baruch, Keren, Keren-Zur, Yael, Haviv, Ofra, Filippi, Massimo, Petrou, Panayiota, Hajag, Shalom, Vourka-Karussis, Urania, Vaknin-Dembinsky, Adi, Khoury, Salim, Abramsky, Oded, Atlan, Henri, Cohen, Irun R, Abulafia-Lapid, Rivka
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 14-12-2012; Public Library of Science (PLoS)
• Subjects: Adult; Antigens; Biology; Biophysics; Cell lines; Clinical trials; Cloning; Disease-Free Survival; Double-Blind Method; Double-blind studies; Feasibility studies; Female; Humans; Immunology; Irradiation; Lymphocytes; Lymphocytes - cytology; Lymphocytes T; Magnetic resonance imaging; Male; Medical research; Medicine; Multiple sclerosis; Multiple Sclerosis, Chronic Progressive - therapy; Myelin; Myelin proteolipid protein; Myelin Sheath - chemistry; Myelin Sheath - metabolism; Neurology; Nuclear medicine; Oligodendrocyte-myelin glycoprotein; Pathogenesis; Patients; Peptides; Peptides - chemistry; Peripheral blood; Phenotype; Placebos; Proteins; Radiation; Randomization; Recurrence; Review boards; Safety; T cell receptors; T cells; T-Lymphocytes - cytology; Time Factors; Vaccination; Vaccines; Walking; Jerusalem Israel; Israel
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0050478

T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled.
To evaluate the safety and efficacy of TCV in progressive MS, in a double-blind, controlled clinical trial.
Twenty-six patients with relapsing-progressive MS were enrolled in the study (mean age: 39±9.8 years; mean EDSS: 4.4±1.7). T-cell lines reactive to 9 different peptides of the myelin antigens, MBP, MOG and PLP were raised from the patients' peripheral blood. The patients were randomized into two groups: 19 were treated with TCV (four subcutaneous injections of 10-30×10(6) T-cells, attenuated by irradiation, on days 1, 30, 90 and 180) and 7 patients were treated with sham injections. Twenty-four patients (17 in the TCV group and 7 in the placebo) were eligible for per-protocol analysis.
At one year following the inclusion, an increase in the EDSS (+0.50) and an increase in 10-meter walking time (+0.18 sec), were observed in the placebo group; in the TCV group there was a decrease in the EDSS (-0.44; p<0.01) and in the 10-meter walking time (0.84 sec; p<0.005). Sixteen of the 17 patients (94.1%) in the TCV group remained relapse-free during the year of the study, as compared to 42.9% in the placebo group (p = 0.01 and p = 0.03 with adjustment). The proportion of patients with any relapse during the year of the study in the TCV-group, was reduced by 89.6%., as compared to the placebo-treated group. MRI parameters did not change significantly.
This is the first controlled, double-blind trial with TCV in progressive MS. The results demonstrate the feasibility and safety of the procedure, and provide significant indications of clinical efficacy. Further studies with larger groups of subjects are warranted.
ClinicalTrials.gov NCT01448252.